A Game-Changing Advance in TB Diagnostics: NEJM Publishes Landmark Validation of the Pluslife MiniDock MTB Test

A Game-Changing Advance in TB Diagnostics: NEJM Publishes Landmark Validation of the Pluslife MiniDock MTB Test

Groundbreaking research published in The New England Journal of Medicine validated the near-point-of-care molecular test across 7 high-burden tuberculosis countries. This innovative diagnostic demonstrated exceptional performance:

• Sputum: 85.7% sensitivity, 97.6% specificity
• Tongue swab: 79.6% sensitivity, 99.5% specificity

Both modalities met WHO target product profiles for TB diagnostics.

Comparative Diagnostic Performance:
     ✓ Sputum sensitivity comparable to Xpert MTB/RIF Ultra (only 2.8 percentage points lower)
     ✓ Sputum sensitivity is 24.3 percentage points higher than conventional smear microscopy
    ✓ Validated non-invasive tongue swab option for patients unable to produce sputum
    ✓ Excellent usability scores (median 75/100) enabling deployment in resource-limited settings
    ✓ Cost-effective design suitable for peripheral health facilities and decentralized testing

This technology represents a critical advancement in closing the persistent gap between estimated and notified TB cases globally, accelerating progress toward END TB goals through expanded access to high-quality molecular diagnostics at the point of need.

Reference:

Yerlikaya S, Chirwa M, Cattamanchi A, et al. Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples. N Engl J Med. 2026;394(17):1710-1722. doi:10.1056/NEJMoa2509761